← SynDRA
SELEGILINE
SynDRA canonical compound SYN0002820 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | MAOB |
|---|
| Mechanism of action | Monoamine oxidase inhibitor |
|---|
| Indication | Parkinson's Disease |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- MAOB
- MAOA
- ADRA2A
- ADRA2B
- CYP2B6
- CYP2C19
- Maoa
- Maob
- SNCA
- TACR1
Mechanisms of action (all sources)
- Monoamine oxidase inhibitor
- MAOB INHIBITOR
- Monoamine oxidase B inhibitor
- TACR1 ANTAGONIST
- MAOB MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADRA2C
- OPRK1
- ABCB1
- HTR2B
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- LCK
- KDM1A
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2A
- MMP1
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- HDAC8
- HDAC6
- HDAC5
- HDAC3
- HDAC2
- HDAC11
- HDAC1
- GMNN
- MLNR
- MMP9
- FYN
- PTGS1
- TBXAS1
- TBXA2R
- TACR2
- SLC6A4
- SLC6A3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Monoamine Oxidase Inhibitors
- Anti-Dyskinesia Agents
- Antidepressive Agents
- Antiparkinson Agents
- Central Nervous System Agents
- Enzyme Inhibitors
- Neuroprotective Agents
- Protective Agents
- Psychotropic Drugs
- Monoamine Oxidase Inhibitor
- Monoamine Oxidase-B Inhibitors
- Monoamine Oxidase Type B Inhibitor
ATC classes
- N04B · DOPAMINERGIC AGENTS
Cross-references
Synonyms
- Anipryl
- ELDEPRYL
- EMSAM
- Emsam
- SELEGILINE HYDROCHLORIDE
- ZELAPAR
- Zelapar
- (-)-deprenil
- (-)-deprenyl
- (-)-selegiline
- (r)-(-)-deprenyl
- (r)-selegiline
- anipryl
- l-deprenyl
- selegina
- selgene
- zelapar
- selegiline hydrochloride
- selegiline HCl
- Selegilina
- L-selegiline
- Selegiline Hydrochloride
- Selegiline Hcl
- (-)-Deprenyl hydrochloride
- l-Deprenyl hydrochloride
- Jumex hydrochloride
- Eldepryl hydrochloride
- (-)-Deprenil hydrochloride
- (-)-E-250 hydrochloride
- UNII-6W731X367Q
- HSDB 7183
- R-(-)-Deprenyl (hydrochloride)
- FPF1100
- (-)-Phenylisopropylmethylpropynylamine
- 6W731X367Q
- Zydis selegiline
- L-Deprenalin
- Selegilinum
Reported adverse events
- Pain
- Hallucination
- Headache
- Nausea
- Dry mouth
- Dizziness
- Dyskinesia
- Insomnia
- Anxiety
- Lethargy
- Malaise
- Palpitations
Look up SELEGILINE in the interactive SynDRA portal →